What is Zacks Research’s Forecast for Alkermes Q1 Earnings?

Alkermes plc (NASDAQ:ALKS) – Stock analysts at Zacks Research decreased their Q1 2025 earnings estimates for Alkermes in a research report issued to clients and investors on Wednesday, April 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.28 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.33 EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.43 EPS, FY2026 earnings at $1.24 EPS and FY2027 earnings at $1.14 EPS.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, February 14th. UBS Group raised shares of Alkermes from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $21.00 to $38.00 in a report on Tuesday, March 4th. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. HC Wainwright reiterated a “neutral” rating and issued a $46.00 price target on shares of Alkermes in a research report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Alkermes from $40.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Alkermes Trading Up 1.5 %

Shares of ALKS opened at $27.94 on Monday. The firm has a fifty day simple moving average of $33.00 and a two-hundred day simple moving average of $30.46. The firm has a market cap of $4.61 billion, a PE ratio of 12.88, a P/E/G ratio of 2.20 and a beta of 0.39. Alkermes has a 1-year low of $22.90 and a 1-year high of $36.45.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.89% of the company’s stock.

Institutional Trading of Alkermes

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fifth Third Bancorp grew its position in shares of Alkermes by 54.4% during the first quarter. Fifth Third Bancorp now owns 1,479 shares of the company’s stock valued at $49,000 after purchasing an additional 521 shares in the last quarter. USA Financial Formulas bought a new position in Alkermes during the first quarter valued at approximately $49,000. SG Americas Securities LLC grew its holdings in Alkermes by 25.8% during the 1st quarter. SG Americas Securities LLC now owns 13,988 shares of the company’s stock valued at $462,000 after buying an additional 2,872 shares in the last quarter. Avanza Fonder AB bought a new stake in Alkermes in the 1st quarter worth approximately $266,000. Finally, GAMMA Investing LLC increased its stake in Alkermes by 31.9% in the 1st quarter. GAMMA Investing LLC now owns 5,396 shares of the company’s stock worth $178,000 after acquiring an additional 1,305 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.